Bioverativ (NASDAQ:BIVV) had its price objective upped by Royal Bank of Canada to $68.00 in a research note released on Thursday. The firm currently has a market perform rating on the biotechnology company’s stock.
Several other research analysts also recently weighed in on BIVV. Argus upgraded Bioverativ from a hold rating to a buy rating and set a $64.00 price target for the company in a research note on Wednesday, September 20th. Morgan Stanley restated an underweight rating and issued a $47.00 price target (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Zacks Investment Research raised Bioverativ from a hold rating to a strong-buy rating and set a $69.00 price objective on the stock in a report on Thursday, October 19th. Piper Jaffray Companies reaffirmed an overweight rating and set a $71.00 price objective on shares of Bioverativ in a report on Monday, October 23rd. Finally, Deutsche Bank set a $53.00 price objective on Bioverativ and gave the stock a hold rating in a report on Monday, November 20th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $62.53.
Bioverativ (NASDAQ BIVV) traded up $1.36 during mid-day trading on Thursday, reaching $64.11. The company’s stock had a trading volume of 712,830 shares, compared to its average volume of 994,808. Bioverativ has a 1-year low of $40.99 and a 1-year high of $65.09. The company has a market cap of $6,940.00 and a P/E ratio of 15.67.
Institutional investors and hedge funds have recently modified their holdings of the company. Advisors Asset Management Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth approximately $137,000. TCI Wealth Advisors Inc. purchased a new stake in Bioverativ during the 3rd quarter valued at $186,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in Bioverativ during the 3rd quarter valued at $190,000. Canada Pension Plan Investment Board purchased a new stake in Bioverativ during the 3rd quarter valued at $194,000. Finally, ACG Wealth purchased a new stake in Bioverativ during the 3rd quarter valued at $205,000. 96.03% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://weekherald.com/2018/01/19/bioverativ-bivv-price-target-increased-to-68-00-by-analysts-at-royal-bank-of-canada.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.